uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressGlobeNewsWire • 05/09/25
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's DataSeeking Alpha • 05/08/25
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130Seeking Alpha • 04/21/25
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 04/17/25
uniQure Announces 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/27/25
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval BeckonsSeeking Alpha • 02/20/25
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsBenzinga • 02/07/25
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BPRNewsWire • 02/07/25
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseGlobeNewsWire • 02/03/25
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSGlobeNewsWire • 01/30/25
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?The Motley Fool • 12/15/24
QURE Soars on FDA Alignment for Speedy Approval of Huntington's DrugZacks Investment Research • 12/11/24
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's DrugInvestors Business Daily • 12/10/24
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's DiseaseGlobeNewsWire • 12/10/24
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a BetZacks Investment Research • 11/29/24
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyGlobeNewsWire • 11/21/24